National Comprehensive Cancer Network

About NCCN

NCCN Flash Update: NCCN Resources for Chronic Myeloid Leukemia, Non-Small Cell Lung Cancer, & Melanoma

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the NCCN Drugs & Biologics Compendium (NCCN Compendium®), and the NCCN Guidelines® with NCCN Evidence Blocks™ for Chronic Myeloid Leukemia. These NCCN Guidelines are currently available as Version 3.2018.

  • Chronic phase CML: Primary Treatment (CML-2)

    • Bosutinib added as a treatment option for any risk score. This is a category 1 recommendation.

    • Intermediate- or high-risk score: Nilotinib recommendation changed from a category 2A to category 1.

    • Intermediate- or high-risk score: Dasatinib recommendation changed from a category 2A to category 1.

    • Footnote d modified: Long-term follow-up data from the DASISION and ENESTnd trials and preliminary data from the BFORE trial suggest that patients with an intermediate- or high-risk Sokal or Hasford score may preferentially benefit from second generation TKI (dasatinib, nilotinib, or bosutinib). See Discussion for additional information.
       

  • The Discussion section has been updated to reflect the changes in the algorithm. (MS-1)
     

*For your reference, the previous update (Version 2.2018) to the NCCN Guidelines for Chronic Myeloid Leukemia, published on October 19, 2017, is available at the following link: https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf

 

NCCN has published updates to the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks, NCCN Compendium®, NCCN Radiation Therapy Compendium™, and NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™) for Non-Small Cell Lung Cancer. These NCCN Guidelines are currently available as Version 2.2018.

  • The Discussion section has been updated to reflect the changes in the algorithm. (MS-1)

*For your reference, the previous update (Version 2.2018) to the NCCN Guidelines for Non-Small Cell Lung Cancer, published on November 17, 2017, is available at the following link: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

 

NCCN has published updates to the following NCCN Guidelines for Patients®:

  • Melanoma, Version 2018

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Compendium, the NCCN Biomarkers Compendium®, the NCCN Templates, the NCCN Radiation Therapy Compendium™, and the NCCN Imaging AUC™, please visit NCCN.org.

To view the NCCN Guidelines for Patients®, please visit NCCN.org/patients.

Free NCCN Guidelines apps for iPhone, iPad, and Android smartphones & tablets are now available! Visit NCCN.org/apps

About NCCN Flash Updates™ 
NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium®, and other NCCN Content. 

Subscribe to NCCN Flash Updates™ 

National Comprehensive Cancer Network® (NCCN®)
275 Commerce Drive, Suite 300
Fort Washington, PA 19034
Telephone: +1 215.690.0300 Fax: +1 215.690.0280 

Access information on permissions and licensing of NCCN Content  

© 2017 National Comprehensive Cancer Network. All Rights Reserved.